Complete response of colorectal liver metastases after intra-arterial chemotherapy

Tumori

Volumn 94, Issue 4, 2008, Pages 489-492

  Fiorentini, Giammaria ^a   Del Conte, Alessandro ^a   De Simone, Michele ^a   Guadagni, Stefano ^b   Mambrini, Andrea ^c   D'Alessandro, Michelina ^a   Aliberti, Camillo ^d   Rossi, Giuseppe ^e   Cantore, Maurizio ^c  

^a SAN GIUSEPPE HOSPITAL   (Italy)

^b UNIVERSITY OF L'AQUILA   (Italy)

^c Department of Oncology   (Italy)

^d Delta Hospital   (Italy)

^e RIZZOLI ORTHOPAEDIC INSTITUTE   (Italy)

Author keywords

Colorectal cancer; Intra arterial chemotherapy; Liver metastases

Indexed keywords

ANTINEOPLASTIC AGENT; FLOXURIDINE;

ARTICLE; CANCER RECURRENCE; CANCER SURGERY; COLORECTAL CANCER; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; FOLLOW UP; HISTOPATHOLOGY; HUMAN; LIVER METASTASIS; MAJOR CLINICAL STUDY; TREATMENT RESPONSE; ULTRASOUND;

EID: 54749114787     PISSN: 03008916     EISSN: None     Source Type: Journal    
DOI: 10.1177/030089160809400408     Document Type: Article

References (24)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu I, Murray T, Thun MJ: Cancer statistic, 2005. CA Cancer J Clin, 55: 10-30, 2005.
2. Gill S, Thomas RR, Goldberg RM: Review article: colorectal cancer chemotherapy. Aliment Pharmacol Ther, 18: 683-692, 2003.
3. Adam R, Avisar E, Ariche A, Giachetti S, Azoulay D, Castaing D, Kunstlinger F, Levi F, Bismuth F: Five-year survival following hepatic resection after neoadjuvant therapy for nonresectable colorectal. Ann Surg Oncol, 8: 347-353, 2001.
4. Adam R: Chemotherapy and surgery: New perspectives on the treatment of unresectable liver metastases. Ann Oncol, (suppl 2) 14: ii13-ii16, 2003.
5. Alberts SR, Horvath WL, Sternfeld WC, Goldberg RM, Mahoney MR, Dakhil SR, Levitt R, Rowland K, Nair S, Sargent DJ, Donohue JH: Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: a North Central Cancer Treatment Group Phase II study. J Clin Oncol, 23: 9243-9249, 2005.
6. Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ, Maroun JA, Ackland SP, Locker PK, Pirotta N, Elfring GL, Miller LL: Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer: Irinotecan Study Group. N Engl J Med, 343: 905-914, 2000.
7. Goldberg RM, Sargent DJ, Morton RF, Fuchs CS, Ramanathan RK, Williamson SK, Findlay BP, Pitot HC, Alberts SR: A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol, 22: 23-30, 2004.
8. Rothenberg ML, Oza AM, Bigelow RH, Berlin JD, Marshall JL, Ramanathan RK, Hart LL, Gupta S, Garay CA, Burger BG, Le Bail N, Haller DG: Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial. J Clin Oncol, 21: 2059-2069, 2003.
9. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med, 350: 2335-2342, 2004.
10. Chen HX, Mooney M, Boron M, Vena D, Mosby K, Grochow L, Jaffe C, Rubinstein L, Zwiebel J, Kaplan RS : Phase II multicenter trial of bevacizumab plus fluorouracil and leucovorin in patients with advanced refractory colorectal cancer: an NCI treatment referral center trial TRC-0301. J Clin Oncol 24: 3354-3360, 2006.
11. Cunningham E, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, Bets D, Mueser M, Harstrick A, Verslype C, Chau I, Van Cutsem E: Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med, 351: 337-345, 2004.
12. Saltz LB, Lenz H, Hochster H, Hochster HS, Wadler S, Hoff PM, Kemeny NE, Hollywood EM, Gonen M, Quinones M, Morse M, Chen HX: Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 study. J Clin Oncol, 25:4557-4561, 2007.
13. Schrag D: The price tag on progress. Chemotherapy for colorectal cancer. N Engl J Med, 351: 317-319, 2004.
14. Aloia T, Sebagh M, Plasse M, Karam V, Levi F, Giacchetti S, Azoulay D, Bismuth H, Castaing D, Adam R: Liver histology and surgical outcomes after preoperative chemotherapy with fluorouracil plus oxaliplatin in colorectal liver metastases. J Clin Oncol, 24: 4983-4990, 2006.
15. Benoist S, Brouquet A, Penna C, Julié C, El Hajjam M, Chagnon S, Mitry E, Rougier P, Nordlinger B: Complete response of colorectal liver metastases after chemotherapy: does it mean cure? J Clin Oncol, 24: 3939-3945, 2006.
16. Machi J, Oishi AJ, Sumida K, Sakamoto K, Furumoto NL, Oishi RH, Kylstra JW: Long-term outcome of radiofrequency ablation for unresectable liver metastases from colorectal cancer: evaluation of prognostic factors and effectiveness in first- and second-line management. Cancer J, 12: 318-326, 2006.
17. Berber E, Pelley R, Siperstein AE: Predictors of survival after radiofrequency thermal ablation of colorectal cancer metastases to the liver: a prospective study. J Clin Oncol, 23: 1358-1364, 2005.
18. Fiorentini G, Rossi S, Bernardeschi P, Cantore M, Guadagni S: Is there a new drug beyond floxuridine for intra-arterial hepatic chemotherapy in liver metastases from colorectal cancer? J Clin Oncol, 23: 2105, 2005.
19. Fiorentini G, Rossi S, Dentico P, Meucci F, Bonechi F, Bernardeschi P, Cantore M, Guadagni S, De Simone M: Oxaliplatin hepatic arterial infusion chemotherapy for hepatic metastases from colorectal cancer: a phase I-II clinical study. Anticancer Res, 24: 2093-2096, 2004.
20. Fiorentini G, Rossi S, Dentico P, Bernardeschi P, Calcinai A, Bonechi F, Cantore M, Guadagni S, De Simone M: Irinotecan hepatic arterial infusion chemotherapy for hepatic metastases from colorectal cancer: a phase II clinical study. Iurnori, 89: 382-384, 2003.
21. Aliberti C, Tilli M, Benea G, Fiorentini G: Trans-arterial chemoembolization (TACE) of liver metastases from colorectal cancer using irinotecan-eluting beads: preliminary results. Anticancer Res, 26: 3793-3795, 2006.
22. Fiorentini G, Aliberti C, Tilli M, Benea G: Transarterial chemoembolization (TACE) of liver metastases (LM) from colorectal cancer (CRC) using irinotecan-eluting beads. 2007 Gastrointestinal Cancers Symposium, Program/Proceedings, p 261, Abstract 356, 2007.
23. Mocellin S, Pilati P, Lise M. Nitti D: Meta-analysis of hepatic arterial infusion for unresectable liver metastases from colorectal cancer: the end of an era? J Clin Oncol, 25: 5649-5654, 2007.
24. Tassinari D: Surrogate end points of quality of life assessment: have we really found what we are looking for? Health Qual Life Outcomes, 24: 71-77, 2003.